| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangiopancreatography, Endoscopic Retrograde | 60 | 2023 | 348 | 14.900 |
Why?
|
| Pancreatitis | 35 | 2021 | 279 | 8.790 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 19 | 2021 | 240 | 5.110 |
Why?
|
| Stents | 26 | 2022 | 657 | 3.860 |
Why?
|
| Endoscopy, Gastrointestinal | 15 | 2021 | 171 | 3.340 |
Why?
|
| Endosonography | 18 | 2023 | 177 | 3.020 |
Why?
|
| Drainage | 14 | 2023 | 133 | 2.920 |
Why?
|
| Indomethacin | 10 | 2020 | 107 | 2.900 |
Why?
|
| Choledocholithiasis | 6 | 2017 | 14 | 2.670 |
Why?
|
| Pancreatitis, Chronic | 5 | 2022 | 168 | 2.140 |
Why?
|
| Pancreatic Cyst | 4 | 2018 | 16 | 2.080 |
Why?
|
| Cholestasis | 6 | 2021 | 90 | 2.050 |
Why?
|
| Sphincterotomy, Endoscopic | 8 | 2022 | 79 | 1.910 |
Why?
|
| Gastric Bypass | 5 | 2021 | 83 | 1.910 |
Why?
|
| Gastrostomy | 7 | 2020 | 110 | 1.850 |
Why?
|
| Endoscopy | 8 | 2020 | 464 | 1.840 |
Why?
|
| Humans | 149 | 2023 | 68618 | 1.780 |
Why?
|
| Pancreatic Ducts | 8 | 2021 | 76 | 1.770 |
Why?
|
| Pancreas | 6 | 2018 | 225 | 1.710 |
Why?
|
| Endoscopic Mucosal Resection | 7 | 2021 | 9 | 1.590 |
Why?
|
| Colonoscopy | 9 | 2021 | 156 | 1.550 |
Why?
|
| Postoperative Complications | 12 | 2021 | 1615 | 1.400 |
Why?
|
| Ultrasonography, Interventional | 5 | 2020 | 119 | 1.380 |
Why?
|
| Stomach Neoplasms | 4 | 2022 | 64 | 1.370 |
Why?
|
| Esophageal Neoplasms | 7 | 2021 | 150 | 1.350 |
Why?
|
| Gastrointestinal Diseases | 5 | 2021 | 107 | 1.340 |
Why?
|
| Barrett Esophagus | 7 | 2021 | 57 | 1.210 |
Why?
|
| Bile Duct Neoplasms | 4 | 2021 | 39 | 1.170 |
Why?
|
| Administration, Rectal | 13 | 2020 | 26 | 1.130 |
Why?
|
| Colorectal Neoplasms | 6 | 2015 | 561 | 1.130 |
Why?
|
| Cholangiography | 3 | 2016 | 55 | 1.110 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 4 | 2016 | 20 | 1.110 |
Why?
|
| Retrospective Studies | 38 | 2021 | 7277 | 1.100 |
Why?
|
| Sigmoidoscopy | 5 | 2015 | 38 | 1.100 |
Why?
|
| Gastrointestinal Hemorrhage | 4 | 2021 | 185 | 1.090 |
Why?
|
| Female | 70 | 2023 | 38074 | 1.070 |
Why?
|
| Colonic Polyps | 5 | 2021 | 63 | 1.060 |
Why?
|
| Endoscopy, Digestive System | 5 | 2021 | 78 | 1.050 |
Why?
|
| Cholecystectomy, Laparoscopic | 3 | 2014 | 59 | 1.050 |
Why?
|
| Male | 67 | 2023 | 37321 | 1.050 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2021 | 40 | 1.050 |
Why?
|
| Lithotripsy | 3 | 2020 | 18 | 1.040 |
Why?
|
| Biliary Tract Diseases | 3 | 2017 | 50 | 1.030 |
Why?
|
| Treatment Outcome | 32 | 2022 | 7029 | 1.030 |
Why?
|
| Pancreatic Neoplasms | 5 | 2020 | 332 | 1.030 |
Why?
|
| Esophagoscopy | 8 | 2021 | 72 | 1.000 |
Why?
|
| Liver Transplantation | 4 | 2013 | 400 | 1.000 |
Why?
|
| Cholangitis | 3 | 2021 | 15 | 0.990 |
Why?
|
| Bilirubin | 2 | 2016 | 51 | 0.970 |
Why?
|
| Middle Aged | 52 | 2023 | 21147 | 0.970 |
Why?
|
| Early Detection of Cancer | 6 | 2015 | 454 | 0.960 |
Why?
|
| Adenocarcinoma | 6 | 2021 | 475 | 0.930 |
Why?
|
| Gallbladder | 3 | 2014 | 15 | 0.920 |
Why?
|
| Gastroenterology | 5 | 2020 | 98 | 0.910 |
Why?
|
| Gastroenterologists | 2 | 2020 | 11 | 0.910 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2020 | 504 | 0.900 |
Why?
|
| Surgical Instruments | 6 | 2021 | 44 | 0.880 |
Why?
|
| Aged | 41 | 2021 | 14862 | 0.850 |
Why?
|
| Islets of Langerhans | 2 | 2020 | 87 | 0.800 |
Why?
|
| Proton Pump Inhibitors | 2 | 2020 | 91 | 0.790 |
Why?
|
| Patient Selection | 6 | 2019 | 592 | 0.780 |
Why?
|
| Pancreatectomy | 2 | 2020 | 129 | 0.770 |
Why?
|
| Gallstones | 4 | 2018 | 58 | 0.770 |
Why?
|
| Islets of Langerhans Transplantation | 2 | 2020 | 101 | 0.760 |
Why?
|
| Pancreatitis, Acute Necrotizing | 3 | 2021 | 11 | 0.760 |
Why?
|
| Calculi | 1 | 2020 | 7 | 0.730 |
Why?
|
| Histamine H2 Antagonists | 1 | 2020 | 45 | 0.730 |
Why?
|
| Cholecystectomy | 2 | 2018 | 79 | 0.730 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2017 | 931 | 0.720 |
Why?
|
| Ampulla of Vater | 2 | 2020 | 34 | 0.700 |
Why?
|
| Risk Assessment | 11 | 2020 | 2007 | 0.690 |
Why?
|
| Peptic Ulcer Hemorrhage | 2 | 2010 | 26 | 0.680 |
Why?
|
| Evidence-Based Medicine | 3 | 2018 | 438 | 0.670 |
Why?
|
| Catheterization | 4 | 2020 | 209 | 0.660 |
Why?
|
| Pain | 2 | 2022 | 472 | 0.660 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2010 | 85 | 0.650 |
Why?
|
| Adult | 32 | 2021 | 21403 | 0.640 |
Why?
|
| Debridement | 2 | 2016 | 55 | 0.640 |
Why?
|
| Risk Factors | 18 | 2020 | 5731 | 0.630 |
Why?
|
| Diclofenac | 2 | 2014 | 11 | 0.620 |
Why?
|
| Liver | 2 | 2023 | 1118 | 0.620 |
Why?
|
| United States | 22 | 2022 | 7367 | 0.610 |
Why?
|
| Lipase | 2 | 2021 | 16 | 0.590 |
Why?
|
| Duodenoscopes | 3 | 2023 | 7 | 0.580 |
Why?
|
| Chemoprevention | 2 | 2015 | 26 | 0.580 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 143 | 0.580 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 154 | 0.570 |
Why?
|
| Alanine Transaminase | 2 | 2021 | 137 | 0.570 |
Why?
|
| Clinical Competence | 2 | 2020 | 657 | 0.560 |
Why?
|
| Methylene Blue | 1 | 2016 | 16 | 0.560 |
Why?
|
| Myotomy | 3 | 2021 | 14 | 0.560 |
Why?
|
| Pain Management | 1 | 2018 | 186 | 0.560 |
Why?
|
| Coloring Agents | 1 | 2016 | 66 | 0.550 |
Why?
|
| Bile Duct Diseases | 2 | 2014 | 28 | 0.550 |
Why?
|
| Intestinal Perforation | 2 | 2015 | 35 | 0.540 |
Why?
|
| Gastric Outlet Obstruction | 1 | 2016 | 5 | 0.540 |
Why?
|
| Lipoma | 1 | 2016 | 24 | 0.530 |
Why?
|
| Sigmoid Diseases | 1 | 2015 | 8 | 0.520 |
Why?
|
| Foreign Bodies | 1 | 2016 | 58 | 0.520 |
Why?
|
| Gastroscopy | 3 | 2011 | 45 | 0.520 |
Why?
|
| Sphincter of Oddi | 3 | 2021 | 51 | 0.520 |
Why?
|
| Duodenoscopy | 1 | 2015 | 15 | 0.520 |
Why?
|
| Occult Blood | 2 | 2015 | 48 | 0.520 |
Why?
|
| Duodenal Diseases | 1 | 2015 | 15 | 0.520 |
Why?
|
| Laparoscopy | 3 | 2017 | 237 | 0.510 |
Why?
|
| Severity of Illness Index | 6 | 2021 | 1851 | 0.510 |
Why?
|
| Self Expandable Metallic Stents | 4 | 2021 | 14 | 0.500 |
Why?
|
| Diverticulum | 1 | 2015 | 29 | 0.500 |
Why?
|
| Device Removal | 1 | 2016 | 100 | 0.500 |
Why?
|
| Iatrogenic Disease | 2 | 2015 | 36 | 0.500 |
Why?
|
| Adenoma | 2 | 2013 | 132 | 0.490 |
Why?
|
| Unnecessary Procedures | 1 | 2015 | 49 | 0.480 |
Why?
|
| Pandemics | 5 | 2020 | 352 | 0.480 |
Why?
|
| Sensitivity and Specificity | 7 | 2016 | 1753 | 0.470 |
Why?
|
| Research Design | 2 | 2016 | 729 | 0.470 |
Why?
|
| Double-Balloon Enteroscopy | 1 | 2014 | 4 | 0.470 |
Why?
|
| Pancreatic Pseudocyst | 1 | 2014 | 24 | 0.470 |
Why?
|
| Gastroenterostomy | 1 | 2014 | 8 | 0.470 |
Why?
|
| Acute Disease | 7 | 2022 | 658 | 0.460 |
Why?
|
| Amylases | 1 | 2013 | 17 | 0.460 |
Why?
|
| Cholelithiasis | 1 | 2014 | 66 | 0.460 |
Why?
|
| Endoscopes, Gastrointestinal | 2 | 2015 | 17 | 0.450 |
Why?
|
| Ascitic Fluid | 1 | 2013 | 22 | 0.450 |
Why?
|
| Colonic Neoplasms | 2 | 2013 | 299 | 0.450 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 191 | 0.440 |
Why?
|
| Incidence | 11 | 2022 | 1603 | 0.420 |
Why?
|
| Aftercare | 1 | 2013 | 114 | 0.410 |
Why?
|
| Constriction, Pathologic | 4 | 2023 | 236 | 0.410 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2014 | 626 | 0.410 |
Why?
|
| Anti-Inflammatory Agents | 4 | 2014 | 234 | 0.410 |
Why?
|
| End Stage Liver Disease | 1 | 2012 | 60 | 0.400 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2020 | 14 | 0.400 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 446 | 0.400 |
Why?
|
| Direct Service Costs | 1 | 2011 | 8 | 0.400 |
Why?
|
| Fund Raising | 1 | 2011 | 6 | 0.400 |
Why?
|
| Obesity, Morbid | 1 | 2014 | 172 | 0.390 |
Why?
|
| Hospitalization | 5 | 2021 | 978 | 0.390 |
Why?
|
| Swine | 6 | 2010 | 672 | 0.390 |
Why?
|
| Logistic Models | 6 | 2019 | 1420 | 0.390 |
Why?
|
| Hepatic Duct, Common | 1 | 2011 | 3 | 0.390 |
Why?
|
| Heart Failure, Systolic | 1 | 2011 | 16 | 0.390 |
Why?
|
| Common Bile Duct Diseases | 1 | 2011 | 24 | 0.380 |
Why?
|
| Cholecystostomy | 1 | 2010 | 1 | 0.370 |
Why?
|
| Cholecystitis, Acute | 1 | 2010 | 4 | 0.370 |
Why?
|
| Hemostasis, Surgical | 1 | 2010 | 18 | 0.360 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2010 | 21 | 0.360 |
Why?
|
| Epinephrine | 3 | 2019 | 103 | 0.360 |
Why?
|
| Suture Techniques | 4 | 2016 | 75 | 0.360 |
Why?
|
| Aged, 80 and over | 11 | 2020 | 4848 | 0.360 |
Why?
|
| Natural Orifice Endoscopic Surgery | 2 | 2020 | 24 | 0.360 |
Why?
|
| Peritoneum | 1 | 2010 | 27 | 0.360 |
Why?
|
| Disease Models, Animal | 4 | 2010 | 2550 | 0.360 |
Why?
|
| Disease Transmission, Infectious | 2 | 2020 | 25 | 0.360 |
Why?
|
| North America | 5 | 2021 | 112 | 0.360 |
Why?
|
| Equipment Contamination | 2 | 2020 | 38 | 0.350 |
Why?
|
| Equipment Design | 7 | 2020 | 500 | 0.350 |
Why?
|
| Esophageal Achalasia | 2 | 2020 | 78 | 0.350 |
Why?
|
| Occupational Exposure | 2 | 2021 | 122 | 0.340 |
Why?
|
| Colitis, Ulcerative | 3 | 2014 | 53 | 0.340 |
Why?
|
| Streptococcus milleri Group | 1 | 2009 | 1 | 0.340 |
Why?
|
| Liver Abscess | 1 | 2009 | 9 | 0.340 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2009 | 6 | 0.340 |
Why?
|
| Streptococcal Infections | 1 | 2009 | 53 | 0.330 |
Why?
|
| Bile Ducts | 3 | 2014 | 59 | 0.330 |
Why?
|
| Risk | 4 | 2020 | 563 | 0.320 |
Why?
|
| Hemostasis, Endoscopic | 1 | 2008 | 17 | 0.320 |
Why?
|
| Intensive Care Units | 2 | 2021 | 344 | 0.320 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2012 | 59 | 0.310 |
Why?
|
| Heart-Assist Devices | 1 | 2011 | 221 | 0.310 |
Why?
|
| Multimodal Imaging | 2 | 2020 | 62 | 0.310 |
Why?
|
| Fellowships and Scholarships | 1 | 2008 | 127 | 0.290 |
Why?
|
| Recurrence | 5 | 2020 | 948 | 0.290 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 191 | 0.290 |
Why?
|
| Bacteremia | 1 | 2009 | 155 | 0.290 |
Why?
|
| Hemangioma | 1 | 2007 | 51 | 0.290 |
Why?
|
| Vasoconstrictor Agents | 3 | 2021 | 107 | 0.290 |
Why?
|
| Plastics | 3 | 2022 | 25 | 0.280 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 581 | 0.280 |
Why?
|
| Sphincter of Oddi Dysfunction | 2 | 2020 | 48 | 0.280 |
Why?
|
| Stomach | 4 | 2011 | 80 | 0.280 |
Why?
|
| Personal Protective Equipment | 3 | 2020 | 27 | 0.260 |
Why?
|
| Prospective Studies | 8 | 2021 | 3705 | 0.260 |
Why?
|
| Cohort Studies | 8 | 2020 | 2358 | 0.260 |
Why?
|
| Esophagus | 2 | 2019 | 303 | 0.260 |
Why?
|
| Necrosis | 3 | 2018 | 239 | 0.250 |
Why?
|
| Gallbladder Diseases | 2 | 2015 | 16 | 0.250 |
Why?
|
| Betacoronavirus | 3 | 2020 | 116 | 0.240 |
Why?
|
| Chagas Cardiomyopathy | 1 | 2004 | 3 | 0.240 |
Why?
|
| Biomarkers | 3 | 2015 | 1593 | 0.240 |
Why?
|
| Surveys and Questionnaires | 6 | 2020 | 2800 | 0.220 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2015 | 9 | 0.220 |
Why?
|
| Duodenum | 1 | 2023 | 47 | 0.220 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 378 | 0.210 |
Why?
|
| Young Adult | 8 | 2022 | 5717 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 772 | 0.210 |
Why?
|
| Infection Control | 2 | 2020 | 101 | 0.210 |
Why?
|
| Time Factors | 7 | 2020 | 4655 | 0.200 |
Why?
|
| SEER Program | 2 | 2019 | 153 | 0.200 |
Why?
|
| Anastomotic Leak | 2 | 2019 | 11 | 0.200 |
Why?
|
| Pancreatic Diseases | 2 | 2020 | 66 | 0.200 |
Why?
|
| Zenker Diverticulum | 1 | 2021 | 7 | 0.200 |
Why?
|
| Liver Failure, Acute | 1 | 2021 | 49 | 0.190 |
Why?
|
| Intestinal Mucosa | 2 | 2013 | 219 | 0.190 |
Why?
|
| Forecasting | 2 | 2015 | 277 | 0.190 |
Why?
|
| Fluid Therapy | 1 | 2021 | 59 | 0.190 |
Why?
|
| Predictive Value of Tests | 2 | 2016 | 1465 | 0.190 |
Why?
|
| Midazolam | 1 | 2020 | 46 | 0.180 |
Why?
|
| Urologists | 1 | 2020 | 7 | 0.180 |
Why?
|
| Pancreaticojejunostomy | 1 | 2020 | 21 | 0.180 |
Why?
|
| Gastrointestinal Tract | 1 | 2021 | 63 | 0.180 |
Why?
|
| Michigan | 3 | 2020 | 68 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 67 | 0.180 |
Why?
|
| Esophagectomy | 1 | 2020 | 26 | 0.180 |
Why?
|
| Hydrogen Peroxide | 1 | 2021 | 168 | 0.180 |
Why?
|
| Conscious Sedation | 1 | 2020 | 61 | 0.180 |
Why?
|
| Digestive System Diseases | 1 | 2020 | 16 | 0.180 |
Why?
|
| Balloon Enteroscopy | 1 | 2020 | 2 | 0.180 |
Why?
|
| Gastric Stump | 1 | 2020 | 2 | 0.180 |
Why?
|
| Electrosurgery | 1 | 2020 | 15 | 0.180 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2020 | 46 | 0.180 |
Why?
|
| Chest Pain | 2 | 2019 | 151 | 0.180 |
Why?
|
| Length of Stay | 3 | 2021 | 780 | 0.170 |
Why?
|
| Drug Costs | 1 | 2020 | 87 | 0.170 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 114 | 0.170 |
Why?
|
| Gastrectomy | 1 | 2019 | 24 | 0.170 |
Why?
|
| Geography | 1 | 2019 | 80 | 0.170 |
Why?
|
| Hemostatic Techniques | 1 | 2019 | 23 | 0.170 |
Why?
|
| Plant Oils | 1 | 2019 | 31 | 0.160 |
Why?
|
| Comparative Effectiveness Research | 2 | 2018 | 36 | 0.160 |
Why?
|
| Research | 1 | 2020 | 214 | 0.160 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2019 | 73 | 0.160 |
Why?
|
| Postoperative Hemorrhage | 1 | 2019 | 69 | 0.160 |
Why?
|
| Reproducibility of Results | 3 | 2020 | 2077 | 0.160 |
Why?
|
| Colectomy | 1 | 2019 | 64 | 0.160 |
Why?
|
| Gastrointestinal Agents | 1 | 2019 | 51 | 0.160 |
Why?
|
| Bayes Theorem | 3 | 2015 | 307 | 0.160 |
Why?
|
| Transplantation, Autologous | 1 | 2019 | 145 | 0.160 |
Why?
|
| Myocardial Infarction | 1 | 2004 | 807 | 0.160 |
Why?
|
| Prognosis | 2 | 2017 | 2093 | 0.160 |
Why?
|
| Animals | 8 | 2010 | 20881 | 0.160 |
Why?
|
| Disease Management | 1 | 2020 | 248 | 0.160 |
Why?
|
| Mass Screening | 3 | 2020 | 843 | 0.160 |
Why?
|
| Mental Health | 1 | 2020 | 278 | 0.160 |
Why?
|
| Cross Infection | 1 | 2020 | 195 | 0.150 |
Why?
|
| Feasibility Studies | 2 | 2011 | 652 | 0.150 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 90 | 0.150 |
Why?
|
| Health Personnel | 1 | 2021 | 286 | 0.150 |
Why?
|
| Multiple Chronic Conditions | 1 | 2017 | 9 | 0.150 |
Why?
|
| Colon | 2 | 2020 | 168 | 0.150 |
Why?
|
| Deglutition Disorders | 2 | 2019 | 297 | 0.150 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 42 | 0.150 |
Why?
|
| Risk Adjustment | 1 | 2017 | 49 | 0.150 |
Why?
|
| Propensity Score | 1 | 2017 | 117 | 0.150 |
Why?
|
| Quality Indicators, Health Care | 2 | 2015 | 136 | 0.140 |
Why?
|
| Gastric Balloon | 1 | 2017 | 6 | 0.140 |
Why?
|
| Quality of Life | 3 | 2022 | 1515 | 0.140 |
Why?
|
| Specialization | 1 | 2017 | 66 | 0.140 |
Why?
|
| Education, Medical, Continuing | 2 | 2008 | 136 | 0.140 |
Why?
|
| Adolescent | 5 | 2020 | 8912 | 0.140 |
Why?
|
| Health Care Surveys | 2 | 2020 | 239 | 0.140 |
Why?
|
| Foreign-Body Migration | 1 | 2016 | 38 | 0.140 |
Why?
|
| Double-Blind Method | 3 | 2019 | 1738 | 0.140 |
Why?
|
| Biomedical Research | 1 | 2020 | 310 | 0.140 |
Why?
|
| Primary Prevention | 1 | 2017 | 115 | 0.140 |
Why?
|
| Digestive System Surgical Procedures | 2 | 2020 | 30 | 0.140 |
Why?
|
| Canada | 3 | 2021 | 267 | 0.140 |
Why?
|
| Injections | 1 | 2016 | 119 | 0.140 |
Why?
|
| Deglutition | 1 | 2019 | 221 | 0.140 |
Why?
|
| Diabetes Mellitus | 1 | 2022 | 694 | 0.140 |
Why?
|
| Tissue Banks | 1 | 2016 | 13 | 0.140 |
Why?
|
| Video Recording | 2 | 2014 | 145 | 0.130 |
Why?
|
| Follow-Up Studies | 6 | 2021 | 3259 | 0.130 |
Why?
|
| Stomach Diseases | 1 | 2016 | 22 | 0.130 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 1046 | 0.130 |
Why?
|
| Dilatation | 1 | 2016 | 58 | 0.130 |
Why?
|
| Health Status Disparities | 1 | 2019 | 326 | 0.130 |
Why?
|
| Prophylactic Surgical Procedures | 1 | 2015 | 2 | 0.130 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2015 | 9 | 0.130 |
Why?
|
| Tumor Burden | 1 | 2016 | 132 | 0.130 |
Why?
|
| Microscopy, Confocal | 2 | 2013 | 337 | 0.130 |
Why?
|
| Liver Function Tests | 1 | 2016 | 114 | 0.130 |
Why?
|
| Precancerous Conditions | 1 | 2015 | 74 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2016 | 172 | 0.130 |
Why?
|
| Cost-Benefit Analysis | 2 | 2018 | 504 | 0.130 |
Why?
|
| Endpoint Determination | 1 | 2015 | 82 | 0.130 |
Why?
|
| Cholangiocarcinoma | 1 | 2015 | 20 | 0.120 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 144 | 0.120 |
Why?
|
| Case-Control Studies | 2 | 2021 | 1553 | 0.120 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2014 | 1 | 0.120 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 10 | 0.120 |
Why?
|
| Stress, Psychological | 1 | 2020 | 824 | 0.120 |
Why?
|
| Liability, Legal | 1 | 2014 | 19 | 0.120 |
Why?
|
| Risk Management | 1 | 2014 | 37 | 0.120 |
Why?
|
| Crohn Disease | 1 | 2014 | 38 | 0.120 |
Why?
|
| Quality of Health Care | 2 | 2014 | 322 | 0.110 |
Why?
|
| Disclosure | 1 | 2014 | 45 | 0.110 |
Why?
|
| Tissue Culture Techniques | 1 | 2013 | 62 | 0.110 |
Why?
|
| Ultrasonography | 1 | 2016 | 453 | 0.110 |
Why?
|
| Medically Underserved Area | 1 | 2014 | 85 | 0.110 |
Why?
|
| Hepatitis B, Chronic | 1 | 2013 | 19 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 951 | 0.110 |
Why?
|
| Transplantation | 1 | 2013 | 23 | 0.110 |
Why?
|
| Medical Errors | 1 | 2014 | 80 | 0.110 |
Why?
|
| Abdominal Pain | 2 | 2012 | 97 | 0.110 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 111 | 0.110 |
Why?
|
| Equipment Safety | 2 | 2014 | 50 | 0.100 |
Why?
|
| Esophagitis | 1 | 2012 | 45 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2013 | 86 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 160 | 0.100 |
Why?
|
| ROC Curve | 1 | 2013 | 392 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2013 | 2324 | 0.100 |
Why?
|
| Models, Animal | 2 | 2010 | 252 | 0.100 |
Why?
|
| Algorithms | 2 | 2015 | 1196 | 0.100 |
Why?
|
| Observer Variation | 2 | 2015 | 330 | 0.100 |
Why?
|
| Artificial Intelligence | 1 | 2013 | 159 | 0.100 |
Why?
|
| Lymphocytes | 1 | 2012 | 228 | 0.100 |
Why?
|
| Sus scrofa | 2 | 2009 | 74 | 0.100 |
Why?
|
| Mucous Membrane | 2 | 2011 | 66 | 0.100 |
Why?
|
| Esophageal Stenosis | 1 | 2011 | 36 | 0.100 |
Why?
|
| Transplantation, Heterotopic | 1 | 2011 | 7 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2013 | 163 | 0.100 |
Why?
|
| Omentum | 1 | 2011 | 18 | 0.100 |
Why?
|
| Florida | 1 | 2011 | 221 | 0.090 |
Why?
|
| Decompression, Surgical | 1 | 2011 | 55 | 0.090 |
Why?
|
| Hernia, Abdominal | 1 | 2010 | 7 | 0.090 |
Why?
|
| Pneumoperitoneum | 1 | 2010 | 7 | 0.090 |
Why?
|
| Disinfection | 2 | 2023 | 112 | 0.090 |
Why?
|
| Gastroepiploic Artery | 1 | 2010 | 2 | 0.090 |
Why?
|
| Referral and Consultation | 1 | 2013 | 383 | 0.090 |
Why?
|
| Cadaver | 1 | 2011 | 136 | 0.090 |
Why?
|
| Models, Theoretical | 1 | 2013 | 384 | 0.090 |
Why?
|
| Esophageal Sphincter, Lower | 2 | 2020 | 22 | 0.090 |
Why?
|
| Affinity Labels | 1 | 2010 | 66 | 0.090 |
Why?
|
| Electrocoagulation | 1 | 2010 | 35 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2015 | 1140 | 0.090 |
Why?
|
| Gastric Mucosa | 1 | 2010 | 77 | 0.090 |
Why?
|
| Peptides | 1 | 2013 | 455 | 0.090 |
Why?
|
| Cystectomy | 1 | 2009 | 13 | 0.090 |
Why?
|
| Cystoscopy | 1 | 2009 | 23 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 1174 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2013 | 334 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2009 | 18 | 0.090 |
Why?
|
| Manometry | 2 | 2021 | 276 | 0.090 |
Why?
|
| Artifacts | 1 | 2010 | 125 | 0.090 |
Why?
|
| Models, Biological | 1 | 2013 | 981 | 0.080 |
Why?
|
| Water | 1 | 2010 | 230 | 0.080 |
Why?
|
| Gastroscopes | 1 | 2008 | 2 | 0.080 |
Why?
|
| Meta-Analysis as Topic | 2 | 2021 | 57 | 0.080 |
Why?
|
| Rectum | 1 | 2008 | 62 | 0.080 |
Why?
|
| Polyps | 1 | 2007 | 12 | 0.080 |
Why?
|
| Urinary Bladder | 1 | 2008 | 108 | 0.080 |
Why?
|
| Specimen Handling | 1 | 2007 | 47 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2007 | 242 | 0.070 |
Why?
|
| Esophageal Diseases | 1 | 2007 | 95 | 0.070 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 800 | 0.070 |
Why?
|
| Random Allocation | 1 | 2008 | 442 | 0.070 |
Why?
|
| Interprofessional Relations | 1 | 2008 | 188 | 0.070 |
Why?
|
| Reference Values | 1 | 2007 | 579 | 0.070 |
Why?
|
| Administration, Topical | 2 | 2019 | 111 | 0.070 |
Why?
|
| Triage | 1 | 2007 | 109 | 0.070 |
Why?
|
| Consensus | 2 | 2019 | 211 | 0.070 |
Why?
|
| Ambulatory Care | 1 | 2007 | 340 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 649 | 0.060 |
Why?
|
| Curriculum | 1 | 2008 | 575 | 0.060 |
Why?
|
| Complement Fixation Tests | 1 | 2004 | 3 | 0.060 |
Why?
|
| Trypanosoma cruzi | 1 | 2004 | 7 | 0.060 |
Why?
|
| Infliximab | 2 | 2014 | 16 | 0.060 |
Why?
|
| Adalimumab | 2 | 2014 | 16 | 0.060 |
Why?
|
| Antibodies, Protozoan | 1 | 2004 | 15 | 0.060 |
Why?
|
| Health Status | 2 | 2020 | 429 | 0.060 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 2279 | 0.060 |
Why?
|
| Decision Making | 1 | 2007 | 410 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 1426 | 0.060 |
Why?
|
| Elevators and Escalators | 1 | 2023 | 2 | 0.060 |
Why?
|
| Databases, Factual | 2 | 2018 | 622 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2014 | 151 | 0.050 |
Why?
|
| National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) | 1 | 2022 | 4 | 0.050 |
Why?
|
| Texas | 1 | 2022 | 92 | 0.050 |
Why?
|
| California | 1 | 2022 | 99 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 1619 | 0.050 |
Why?
|
| Diarrhea | 1 | 2021 | 63 | 0.050 |
Why?
|
| Electrocardiography | 1 | 2004 | 601 | 0.050 |
Why?
|
| Data Collection | 1 | 2023 | 420 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 2 | 2014 | 511 | 0.050 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2021 | 40 | 0.050 |
Why?
|
| Echocardiography | 1 | 2004 | 515 | 0.050 |
Why?
|
| Emergencies | 1 | 2021 | 107 | 0.050 |
Why?
|
| Global Health | 1 | 2021 | 136 | 0.050 |
Why?
|
| Ventilation | 1 | 2020 | 3 | 0.050 |
Why?
|
| Workplace | 1 | 2021 | 75 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 238 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2020 | 33 | 0.040 |
Why?
|
| Disposable Equipment | 1 | 2020 | 12 | 0.040 |
Why?
|
| Hypnotics and Sedatives | 1 | 2020 | 96 | 0.040 |
Why?
|
| Appointments and Schedules | 1 | 2020 | 47 | 0.040 |
Why?
|
| Electric Impedance | 1 | 2020 | 131 | 0.040 |
Why?
|
| Internationality | 1 | 2020 | 74 | 0.040 |
Why?
|
| Europe | 1 | 2020 | 196 | 0.040 |
Why?
|
| Respiration, Artificial | 1 | 2021 | 190 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 114 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 191 | 0.040 |
Why?
|
| Mentha piperita | 1 | 2019 | 6 | 0.040 |
Why?
|
| Spain | 1 | 2019 | 34 | 0.040 |
Why?
|
| Palliative Care | 1 | 2021 | 271 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 880 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2020 | 714 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2018 | 7 | 0.040 |
Why?
|
| Medicare | 1 | 2020 | 319 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2017 | 23 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 186 | 0.040 |
Why?
|
| United Kingdom | 1 | 2017 | 152 | 0.040 |
Why?
|
| Metals | 1 | 2018 | 100 | 0.040 |
Why?
|
| Sample Size | 1 | 2016 | 79 | 0.030 |
Why?
|
| Registries | 1 | 2019 | 733 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 1745 | 0.030 |
Why?
|
| Fluorescence | 1 | 2015 | 104 | 0.030 |
Why?
|
| Recovery of Function | 1 | 2019 | 506 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 2016 | 83 | 0.030 |
Why?
|
| Acalculous Cholecystitis | 1 | 2014 | 1 | 0.030 |
Why?
|
| Nitroglycerin | 1 | 2014 | 20 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 1342 | 0.030 |
Why?
|
| Somatostatin | 1 | 2014 | 36 | 0.030 |
Why?
|
| Digestive System Fistula | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hormones | 1 | 2014 | 42 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2014 | 50 | 0.030 |
Why?
|
| Certolizumab Pegol | 1 | 2014 | 1 | 0.030 |
Why?
|
| Tensile Strength | 1 | 2014 | 90 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2014 | 48 | 0.030 |
Why?
|
| Keratin-20 | 1 | 2013 | 3 | 0.030 |
Why?
|
| Mucin-2 | 1 | 2013 | 3 | 0.030 |
Why?
|
| International Cooperation | 1 | 2014 | 88 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 29 | 0.030 |
Why?
|
| Laminin | 1 | 2013 | 62 | 0.030 |
Why?
|
| Vasodilator Agents | 1 | 2014 | 138 | 0.030 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 45 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2013 | 282 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2013 | 103 | 0.030 |
Why?
|
| Cadherins | 1 | 2013 | 93 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2014 | 99 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 2014 | 149 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2013 | 304 | 0.030 |
Why?
|
| Heartburn | 1 | 2012 | 46 | 0.030 |
Why?
|
| Hypothyroidism | 1 | 2012 | 24 | 0.030 |
Why?
|
| Minority Groups | 1 | 2014 | 197 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2013 | 167 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 281 | 0.030 |
Why?
|
| Medicaid | 1 | 2014 | 302 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 737 | 0.020 |
Why?
|
| Collagen | 1 | 2013 | 636 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2013 | 301 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2012 | 318 | 0.020 |
Why?
|
| Early Diagnosis | 1 | 2010 | 122 | 0.020 |
Why?
|
| Calcium | 1 | 2013 | 929 | 0.020 |
Why?
|
| Child | 1 | 2020 | 6405 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 261 | 0.020 |
Why?
|
| Urethra | 1 | 2009 | 56 | 0.020 |
Why?
|
| Suture Anchors | 1 | 2009 | 9 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 489 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 507 | 0.020 |
Why?
|
| Binding Sites | 1 | 2010 | 631 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 1851 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2010 | 597 | 0.020 |
Why?
|
| Disease Progression | 1 | 2010 | 1038 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 2673 | 0.020 |
Why?
|